Related Experiment Video

Updated: Jun 4, 2026

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes
03:53

Growing a Cystic Fibrosis-Relevant Polymicrobial Biofilm to Probe Community Phenotypes

Published on: April 19, 2024

Cefditoren in upper and lower community-acquired respiratory tract infections

Francisco Soriano1, María-José Giménez, Lorenzo Aguilar

  • 1PRISM-AG, Madrid, Spain. fsoriano9@yahoo.com

Drug Design, Development and Therapy
|February 23, 2011
PubMed

Insights

Cefditoren demonstrates high in vitro activity against common respiratory pathogens, including resistant strains. Its pharmacokinetic profile supports effective treatment for community respiratory tract infections.

Area of Science:

  • Pharmacology
  • Infectious Diseases
  • Microbiology

Background:

  • Antibiotic resistance in community respiratory tract infections (RTIs) is a growing concern.
  • Prevalent pathogens include Streptococcus pyogenes, Haemophilus influenzae, and Streptococcus pneumoniae.
  • Understanding cefditoren's efficacy against these evolving resistance patterns is crucial.

Purpose of the Study:

  • To review and update data on cefditoren's activity against prevalent RTI pathogens.
  • To analyze cefditoren's pharmacodynamic activity in relation to its pharmacokinetics.
  • To evaluate clinical efficacy and the correlation between bacterial eradication and clinical outcomes.

Main Methods:

  • In vitro susceptibility testing against surveillance and resistant isolates.
  • Pharmacokinetic and pharmacodynamic (PK/PD) modeling and simulation.
  • Review of clinical studies for tonsillopharyngitis, sinusitis, bronchitis, and pneumonia.
  • Analysis of bacteriological and clinical response data.

Main Results:

  • Cefditoren exhibits high in vitro activity against S. pyogenes, H. influenzae, and S. pneumoniae, including penicillin-nonsusceptible strains.
  • Adequate pharmacodynamic indexes achieved with a twice-daily regimen cover key pathogens.
  • Clinical studies show high bacteriological response rates with cefditoren 400 mg twice daily.
  • A strong correlation exists between bacteriological efficacy and clinical outcomes.

Conclusions:

  • Cefditoren's potent in vitro activity and favorable PK/PD profile support its role in treating community RTIs.
  • The antibiotic demonstrates significant clinical efficacy, even against resistant isolates.
  • Cefditoren is a valuable therapeutic option for managing prevalent respiratory tract infections.
Keywords:
Haemophilus influenzaeStreptococcus pneumoniaeStreptococcus pyogenescefditorencommunity-acquired respiratory tract infections

More Related Videos

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression08:58

Cystic Fibrosis Aggregate Biofilm Model to Study Infection-relevant Gene Expression

Published on: April 18, 2025

Related Concept Videos

Drugs Used in Upper Respiratory Disorders: Overview01:16

Drugs Used in Upper Respiratory Disorders: Overview

Upper respiratory tract disorders, including viral infections and allergic rhinitis, cause significant discomfort and disrupt daily life. Managing these conditions involves a variety of drugs, such as antihistamines, intranasal steroids, decongestants, antitussives, expectorants, and mucolytics. Specific examples of drugs in each category are provided.
Antihistamines (e.g., Benadryl) block histamines from binding. Histamines are chemicals released during an allergic reaction in the body. As a...
Microbiota of the Respiratory Tract01:29

Microbiota of the Respiratory Tract

The human respiratory tract, comprising the upper and lower segments, serves as a critical interface with the external environment. The upper respiratory tract (URT)—including the nostrils, sinuses, pharynx, and oropharynx—is heavily colonized by microbes, while the lower respiratory tract (LRT), composed of the larynx, trachea, bronchi, and lungs, was long thought to be sterile. However, recent molecular studies have revealed that the lungs are not devoid of microbes but act more like...
Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics01:23

Upper Respiratory Drugs: Antitussives, Expectorants, and Mucolytics

Respiratory symptoms, such as congestion and cough, commonly accompany respiratory tract conditions. Various medications, such as antitussives, expectorants, and mucolytics, play crucial roles in providing relief.
Antitussives include codeine, dextromethorphan (Robitussin), and benzonatate (Tessalon). Codeine and dextromethorphan exert their effects centrally by suppressing the cough reflex center in the medulla.  Benzonatate operates peripherally within the respiratory tract by anesthetizing...
Drugs Used in Lower Respiratory Disorders: Overview01:17

Drugs Used in Lower Respiratory Disorders: Overview

Lower respiratory tract disorders present challenges that often require skilled and nuanced approaches for effective management. Common ailments, such as asthma and chronic obstructive pulmonary disease (COPD), have prompted the development of intricate treatment strategies involving bronchodilators and anti-inflammatory drugs, each tailored to ease breathing and revitalize the lungs.
Bronchodilators, the first step of respiration enhancement, come in various forms, each with its own mechanism...
Mechanism of Antibiotic Resistance in MRSA01:25

Mechanism of Antibiotic Resistance in MRSA

Antibiotic resistance in bacteria arises when microorganisms evolve the ability to withstand drugs designed to kill them or inhibit their growth, rendering once-effective treatments useless. This phenomenon, driven by genetic change and selection under antibiotic exposure, poses a profound threat to modern medicine. Mechanisms include drug-inactivating enzymes (e.g., β-lactamases), efflux pumps that eject antibiotics, mutations altering antibiotic targets, decreased drug uptake, and acquisition...
Urinary Tract Infection I: Introduction01:26

Urinary Tract Infection I: Introduction

Urinary tract infections (UTIs) impact various parts of the urinary system, including the kidneys, ureters, bladder, and urethra. These infections are generally bacterial, with Escherichia coli being the most common causative agent, often originating from the gastrointestinal tract. However, other bacteria, such as Staphylococcus saprophyticus, Klebsiella pneumoniae, and Proteus mirabilis, are also known to cause UTIs. The type, location, and underlying complexity of the UTI guide both...